Multiple Myeloma | Clinical

Study Identifies Ideal Ixazomib Triplet Regimen for Newly Diagnosed Multiple Myeloma

April 15, 2021

Ixazomib plus cyclophosphamide, and dexamethasone elicited higher rates of efficacy compared with ixazomib/dexamethasone, followed by single-agent ixazomib maintenance, in patients with transplant-ineligible newly diagnosed multiple myeloma/

The Evolving Treatment Landscape for TCR MM

April 14, 2021

An expert in multiple myeloma shares her perspective on the significance of recent single-agent approvals for patients with triple-class refractory multiple myeloma and highlights promising combination regimens under investigation.